PLEC and pancreatic ductal adenocarcinoma: [64] Moreover, a novel DOTA-based plectin-targeted molecular probe has also shown promise for the diagnosis of PC.[72] A study targeting plectin in three patients with pancreatic ductal adenocarcinoma reported no adverse events, demonstrating its safety.[73] Further studies are needed to validate their clinical performance and safety.